SCHEMBL1947976

SCHEMBL1947976

CCCCCCCC[N+]1=CN(c2c(C)cc(C)cc2C)CC1.F[B-](F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458327 0.80 — —
Hydrochloric Acid SCHEMBL5451642 0.73 — —
Bromide SCHEMBL5441404 0.73 — —
Hydrochloric Acid SCHEMBL5453287 0.73 — —
SCHEMBL1946821 0.72 ALDH1A1 (0.31) HTT
SCHEMBL819057 0.70 — —
SCHEMBL5441368 0.69 — —
SCHEMBL1886914 0.68 HTT (0.43) HTT
SCHEMBL1889199 0.68 HTT (0.43) HTT
SCHEMBL1884343 0.68 HTT (0.43) HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2151446-B1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand RIMTEC CORP (JP) 2016-04-13 — — EP disclosed
EP-2151445-B1 Process for the preparation of bidentate Schiff base ruthenium catalysts containing a salicylaldimine-type ligand RIMTEC CORP (JP) 2015-02-18 — — EP disclosed
US-8338613-B2 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand RIMTEC CORPORATION (JP) 2012-12-25 — — US disclosed
US-20110137043-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand TELENE S.A.S. (FR) 2011-06-09 — — US disclosed
US-20110065925-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand TELENE S.A.S. (FR) 2011-03-17 — — US disclosed
EP-2151446-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand Telene SAS (FR) 2010-02-10 — — EP disclosed
EP-2151445-A1 Process for the preparation of bidentate Schiff base ruthenium cataysts containing a saliclyldimine-type ligand Telene SAS (FR) 2010-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137043-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand SPR, LIG4, SUCLA2 HTT 2717/4885
US-20110065925-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand SPR, LIG4, SUCLA2 HTT 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback